

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/847,936	05/03/2001	H. Kirk Hammond	220002057125	6165
25226	7590 10/01/2003			
	MORRISON & FOERSTER LLP		EXAMINER	
755 PAGE MILL RD PALO ALTO, CA 94304-1018			WEHBE, ANNE MARIE SABRINA	
			ART UNIT	PAPER NUMBER
			1632	24
	•		DATE MAILED: 10/01/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
		09/847,936	HAMMOND ET AL.		
	Office Action Summary	Examiner	Art Unit		
		Anne Marie S. Wehbe	1632		
		nication appears on the cover sheet w	ith the correspondence address		
Period fo	• •				
THE N - Exten after S - If the - If NO - Failum - Any re	MAILING DATE OF THIS COMMUN sions of time may be available under the provision SIX (6) MONTHS from the mailing date of this comperiod for reply specified above is less than thirty (period for reply is specified above, the maximum set or extended period for reply period for reply within the set or extended period for reply period by the Office later than three months	s of 37 CFR 1.136(a). In no event, however, may a	reply be timely filed  ty (30) days will be considered timely.  NTHS from the mailing date of this communication.  BANDONED (35 U.S.C. § 133).		
eamed Status	d patent term adjustment. See 37 CFR 1.704(b).	•			
1)	Responsive to communication(s) f	iled on			
2a)□	This action is <b>FINAL</b> .	2b)⊠ This action is non-final.			
3)□		on for allowance except for formal ma	itters prosecution as to the morito is		
,—		ctice under <i>Ex parte Quayle</i> , 1935 C.			
4)⊠	Claim(s) 1-156 is/are pending in th	e application.			
4	4a) Of the above claim(s) is/a	are withdrawn from consideration.	•		
5)	Claim(s) is/are allowed.				
6)□	Claim(s) is/are rejected.				
7)	Claim(s) is/are objected to.				
8)⊠	Claim(s) <u>1-156</u> are subject to restric	ction and/or election requirement.			
Application	on Papers				
9)[] 7	The specification is objected to by the	ne Examiner.			
10)□ T	he drawing(s) filed on is/are	: a) ☐ accepted or b) ☐ objected to by t	the Examiner.		
	Applicant may not request that any ob-	pjection to the drawing(s) be held in abey	ance. See 37 CFR 1.85(a).		
11) 🗌 T	he proposed drawing correction file	ed on is: a)□ approved b)□ o	disapproved by the Examiner.		
	If approved, corrected drawings are re	equired in reply to this Office action.	·		
12)∐ T	he oath or declaration is objected t	o by the Examiner.			
Priority u	nder 35 U.S.C. §§ 119 and 120				
13)	Acknowledgment is made of a clair	m for foreign priority under 35 U.S.C.	§ 119(a)-(d) or (f).		
a)[	☐ All b)☐ Some * c)☐ None of:				
	1. Certified copies of the priority	documents have been received.			
	2. Certified copies of the priority				
	application from the Inter	s of the priority documents have been national Bureau (PCT Rule 17.2(a)). on for a list of the certified copies not	•		
_a)	☐ The translation of the foreign la	for domestic priority under 35 U.S.C. Inguage provisional application has b	een received.		
	_	for domestic priority under 35 U.S.C.	. 99 120 and/or 121.		
Attachment		<b>∆</b> □ 1-4-	Rumman (DTO 440) Described		
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review ( nation Disclosure Statement(s) (PTO-1449) I	PTO-948) 5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)		

Application/Control Number: 09/847,936

Art Unit: 1632

## **DETAILED ACTION**

## Election/Restrictions

This application contains claims directed to the following patentably distinct species of angiogenic proteins of the claimed invention:

- a) VEGF-A
- b) VEGF-B
- c) VEGF-C
- d) aFGF
- e) bFGF
- f) FGF-4
- g) FGF-5
- h) FGF-6
- i) insulin-like growth factor
- j) angiogenic polypeptide regulator
- k) platelet derived growth factor
- l) hypoxia inducible factor.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from the group of a) -l) listed above for prosecution on the merits to which the claims shall be restricted if

Application/Control Number: 09/847,936

Art Unit: 1632

no generic claim is finally held to be allowable. Currently, claims 1-19, 27, 29-30, 37-83, 91, 93-94, 101-131, 139, 141-142, and 149-156 are generic.

In addition, in regards to claims 29-36, 93-99, and 141-148, the applicant is further required under 35 U.S.C. 121 to elect a single disclosed species of **second** angiogenic protein or peptide from the group of a) -1) listed above for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 29-30, 93-94, and 141-142 are generic for a first angiogenic protein and a second angiogenic protein.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 09/847,936

Art Unit: 1632

Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication from the examiner should be directed to Anne

Marie S. Wehbé, Ph.D., whose telephone number is (703) 306-9156. The examiner can be

reached Monday-Friday from 10:30-7:00. If the examiner is not available, the examiner's

supervisor, Deborah Reynolds, can be reached at (703) 305-4051. General inquiries should be

directed to the group receptionist whose phone number is (703) 308-0196. The technology center

fax number is (703) 872-9306. Please note that Official papers can no longer be received by the

examiner's direct Rightfax number.

Dr. A.M.S. Wehbé

ANNE M. WEHBE' PH.D.
PRIMARY EXAMINER

Reller